Calcutta Serological Institute Laboratory Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 01-01-2025
- Paid Up Capital ₹ 1.00 M
as on 01-01-2025
- Company Age 93 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.13 M
as on 01-01-2025
About Calcutta Serological Institute Laboratory
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company has closed loans amounting to ₹1.13 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Anjali Mazumder, Alakananda Datta, and Madhu Jaria serve as directors at the Company.
- CIN/LLPIN
U85110WB1931PTC007251
- Company No.
007251
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Dec 1931
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Calcutta Serological Institute Laboratory?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anjali Mazumder  | Managing Director | 30-Dec-1986 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Madhu Jaria | Director | 15-Apr-2003 | Current |
| Alakananda Datta | Director | 30-Dec-1986 | Current |
Financial Performance of Calcutta Serological Institute Laboratory.
Calcutta Serological Institute Laboratory Pvt Ltd, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Calcutta Serological Institute Laboratory?
In 2017, Calcutta Serological Institute Laboratory had a promoter holding of 54.00% and a public holding of 46.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Vijaya Bank Creation Date: 30 Jul 2007 | ₹1.13 M | Satisfied |
How Many Employees Work at Calcutta Serological Institute Laboratory?
Calcutta Serological Institute Laboratory has a workforce of 10 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Calcutta Serological Institute Laboratory, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Calcutta Serological Institute Laboratory's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
